Pacific Biosciences of California (NASDAQ:PACB) Stock Price Down 6.8% – Here’s What Happened

Pacific Biosciences of California, Inc. (NASDAQ:PACB) traded down 6.8% during trading on Friday . The stock traded as low as $1.72 and last traded at $1.7150. 4,119,396 shares were traded during trading, a decline of 49% from the average session volume of 8,072,866 shares. The stock had previously closed at $1.84.

Key Pacific Biosciences of California News

Here are the key news stories impacting Pacific Biosciences of California this week:

• Positive Sentiment: Q4 beat on EPS and revenue — PacBio reported a $0.12 loss per share vs. a consensus loss of $0.19 and revenue of $44.65M (roughly in line with estimates), showing an improvement versus a year ago. Pacific Biosciences of California Inc (PACB) Q4 2025 Earnings Call Highlights: Strong Revenue …
• Positive Sentiment: Revenue growth and margin progress — revenue jumped ~14% year-over-year and gross margin expanded to ~41%; management issued 2026 revenue guidance of $165–$180M tied to recent strategic actions, which signals operational improvement. PacBio Q4 Earnings and Revenues Beat Estimates, Gross Margin Up
• Neutral Sentiment: Management materials and transcript available — the company posted the earnings press release, slide deck and call transcript for investors to review execution details and the assumptions behind guidance. Pacific Biosciences Earnings Slide Deck / Press Release
• Negative Sentiment: Company remains unprofitable with large headline metrics — PacBio still posts deep net losses (negative net margin ~325% and negative ROE) and analysts expect FY2026 EPS around -$0.72, meaning continued cash-burn risk and need for execution to reach profitability. Pacific Biosciences of California (PACB) Reports Q4 Loss, Beats Revenue Estimates
• Negative Sentiment: Technical/valuation pressure — the stock is trading below its 50‑day moving average (~$2.09) with high beta and past volatility; market-cap and remaining execution risk make the shares sensitive to guidance tone and near-term results. (Background: market data & technicals)

Analyst Ratings Changes

A number of equities analysts recently commented on PACB shares. Barclays boosted their target price on shares of Pacific Biosciences of California from $1.50 to $2.00 and gave the stock an “equal weight” rating in a research note on Monday, December 15th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Pacific Biosciences of California in a research report on Thursday, January 22nd. Piper Sandler increased their price objective on Pacific Biosciences of California from $1.50 to $2.00 and gave the company a “neutral” rating in a report on Tuesday, November 11th. Finally, Stephens boosted their target price on Pacific Biosciences of California from $1.80 to $2.00 and gave the stock an “overweight” rating in a research note on Monday, November 10th. Three analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Pacific Biosciences of California presently has a consensus rating of “Hold” and an average target price of $2.08.

Pacific Biosciences of California Price Performance

The firm has a market capitalization of $516.26 million, a PE ratio of -0.93 and a beta of 2.27. The company has a current ratio of 6.24, a quick ratio of 5.40 and a debt-to-equity ratio of 17.88. The company has a fifty day moving average price of $2.07 and a two-hundred day moving average price of $1.77.

Pacific Biosciences of California (NASDAQ:PACB) last released its quarterly earnings results on Thursday, February 12th. The biotechnology company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.07. Pacific Biosciences of California had a negative return on equity of 251.75% and a negative net margin of 341.47%.The company had revenue of $44.65 million for the quarter, compared to analyst estimates of $44.60 million. Sell-side analysts forecast that Pacific Biosciences of California, Inc. will post -0.72 earnings per share for the current year.

Institutional Trading of Pacific Biosciences of California

Several institutional investors and hedge funds have recently bought and sold shares of PACB. Amiral Gestion acquired a new stake in shares of Pacific Biosciences of California during the second quarter worth $3,208,000. Geode Capital Management LLC raised its position in Pacific Biosciences of California by 6.4% during the 2nd quarter. Geode Capital Management LLC now owns 6,718,879 shares of the biotechnology company’s stock worth $8,333,000 after buying an additional 401,637 shares during the last quarter. XTX Topco Ltd lifted its stake in shares of Pacific Biosciences of California by 95.5% in the 2nd quarter. XTX Topco Ltd now owns 954,596 shares of the biotechnology company’s stock worth $1,184,000 after acquiring an additional 466,359 shares during the period. Carret Asset Management LLC purchased a new stake in shares of Pacific Biosciences of California in the second quarter valued at about $391,000. Finally, Financial Advocates Investment Management acquired a new position in shares of Pacific Biosciences of California during the second quarter worth about $50,000.

Pacific Biosciences of California Company Profile

Pacific Biosciences of California, Inc develops, manufactures and sells high-performance DNA sequencing systems for genetic and genomic analysis. The company’s proprietary single-molecule, real-time (SMRT) sequencing technology is designed to enable long-read sequencing, offering high accuracy for applications such as de novo genome assembly, transcriptome characterization and structural variation analysis. Pacific Biosciences markets a suite of instruments, including the Sequel and Sequel IIe systems, alongside reagents, consumables and data analysis software to support a range of life science research.

Founded in 2004 and headquartered in Menlo Park, California, Pacific Biosciences has expanded its global reach by serving academic institutions, biotechnology and pharmaceutical companies, and government research centers across North America, Europe and Asia.